Logo image of PTCT

PTC THERAPEUTICS INC (PTCT) Stock Overview

USA - NASDAQ:PTCT - US69366J2006 - Common Stock

67.35 USD
-0.14 (-0.21%)
Last: 10/29/2025, 8:00:01 PM
67.7 USD
+0.35 (+0.52%)
After Hours: 10/29/2025, 8:00:01 PM

PTCT Key Statistics, Chart & Performance

Key Statistics
Market Cap5.35B
Revenue(TTM)1.76B
Net Income(TTM)629.17M
Shares79.44M
Float77.43M
52 Week High69.48
52 Week Low35.95
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)5.67
PE11.88
Fwd PEN/A
Earnings (Next)11-04 2025-11-04/amc
IPO2013-06-20
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


PTCT short term performance overview.The bars show the price performance of PTCT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30

PTCT long term performance overview.The bars show the price performance of PTCT in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150 200 250

The current stock price of PTCT is 67.35 USD. In the past month the price increased by 8.61%. In the past year, price increased by 66.42%.

PTC THERAPEUTICS INC / PTCT Daily stock chart

PTCT Latest News, Press Relases and Analysis

PTCT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.26 397.72B
AMGN AMGEN INC 13.38 157.08B
GILD GILEAD SCIENCES INC 15.31 147.04B
VRTX VERTEX PHARMACEUTICALS INC 24.63 106.97B
REGN REGENERON PHARMACEUTICALS 14.51 69.20B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 63.13B
ARGX ARGENX SE - ADR 89.25 50.61B
INSM INSMED INC N/A 35.29B
ONC BEONE MEDICINES LTD-ADR 5.07 34.58B
NTRA NATERA INC N/A 26.46B
BNTX BIONTECH SE-ADR N/A 24.85B
BIIB BIOGEN INC 9.24 21.68B

About PTCT

Company Profile

PTCT logo image PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company is headquartered in Warren, New Jersey and currently employs 939 full-time employees. The company went IPO on 2013-06-20. The firm is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

Company Info

PTC THERAPEUTICS INC

500 Warren Corporate Center Drive

WARREN NEW JERSEY 07080 US

CEO: Stuart W. Peltz

Employees: 939

PTCT Company Website

PTCT Investor Relations

Phone: 19082227000

PTC THERAPEUTICS INC / PTCT FAQ

What does PTC THERAPEUTICS INC do?

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company is headquartered in Warren, New Jersey and currently employs 939 full-time employees. The company went IPO on 2013-06-20. The firm is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).


Can you provide the latest stock price for PTC THERAPEUTICS INC?

The current stock price of PTCT is 67.35 USD. The price decreased by -0.21% in the last trading session.


What is the dividend status of PTC THERAPEUTICS INC?

PTCT does not pay a dividend.


How is the ChartMill rating for PTC THERAPEUTICS INC?

PTCT has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


How is the market expecting PTCT stock to perform?

23 analysts have analysed PTCT and the average price target is 67.93 USD. This implies a price increase of 0.86% is expected in the next year compared to the current price of 67.35.


What sector and industry does PTC THERAPEUTICS INC belong to?

PTC THERAPEUTICS INC (PTCT) operates in the Health Care sector and the Biotechnology industry.


Should I buy PTCT stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PTCT.


PTCT Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to PTCT. When comparing the yearly performance of all stocks, PTCT is one of the better performing stocks in the market, outperforming 90.63% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

PTCT Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to PTCT. PTCT has an average financial health and profitability rating.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PTCT Financial Highlights

Over the last trailing twelve months PTCT reported a non-GAAP Earnings per Share(EPS) of 5.67. The EPS increased by 226.85% compared to the year before.


Industry RankSector Rank
PM (TTM) 35.65%
ROA 23.89%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%34.65%
Sales Q2Q%-4.19%
EPS 1Y (TTM)226.85%
Revenue 1Y (TTM)96%

PTCT Forecast & Estimates

23 analysts have analysed PTCT and the average price target is 67.93 USD. This implies a price increase of 0.86% is expected in the next year compared to the current price of 67.35.

For the next year, analysts expect an EPS growth of 225.35% and a revenue growth 113.44% for PTCT


Analysts
Analysts78.26
Price Target67.93 (0.86%)
EPS Next Y225.35%
Revenue Next Year113.44%

PTCT Ownership

Ownership
Inst Owners101.79%
Ins Owners0.7%
Short Float %10.09%
Short Ratio6.3